ArticleCancer cell2025
Metabolic engineering to facilitate anti-tumor immunity.
Abstract read
In one paragraph
Article in Cancer cell, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Boosting CAR T cell efficacy in cancer with metabolic insights from design to diet.Nature reviews. Cancer · 2026Review
- Programmable engineered bacteria manipulate metabolism and remodel the TME in situ for enhancing adoptive cell therapy.Molecular therapy : the journal of the American Society of Gene Therapy · 2026Article
- Nutrient stress-induced FTH1 safeguards redox balance and fuels pancreatic ductal adenocarcinoma growth while serving as a therapeutic target and diagnostic biomarker.Cellular oncology (Dordrecht, Netherlands) · 2026Article
- Enhancing persistence while managing cytokine release syndrome to embrace next-generation CAR-T cell therapy.Journal of translational medicine · 2026Review
- Metabolic modulation of immune cell function: mechanisms and therapeutic implications in cancer immunotherapy.Oncogenesis · 2026Review
- Fructose: metabolic signal and modern hazard.Nature metabolism · 2026Review
- Glucose metabolic reprogramming as a driver of immunosuppression in the tumour microenvironment.Clinical and translational medicine · 2026Review
- Metabolic reprogramming of CAR-T cells: a multi-pronged strategy to conquer the immunosuppressive tumor microenvironment.Cell communication and signaling : CCS · 2026Review
- Microglial fructose metabolism is essential for glioblastoma growth.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Advances in CAR-T therapy for central nervous system lymphoma.Frontiers in immunology · 2026Review
- Harnessing cellular immunotherapy for cholangiocarcinoma: an integrated roadmap for overcoming resistance.Frontiers in immunology · 2026Review
- Asparaginase enhances CAR-T cell antitumor immunity by asparagine metabolic reprogramming and central memory induction in ALL.Molecular therapy : the journal of the American Society of Gene Therapy · 2025Article
- Decoding immunometabolism with next-generation tools: lessons from dendritic cells and T cells.The EMBO journal · 2025Review
- Overcoming resistance to anti-PD-L1 immunotherapy: mechanisms, combination strategies, and future directions.Molecular cancer · 2025Review
- Glucose Metabolic Reprogramming in Colorectal Cancer: From Mechanisms to Targeted Therapy Approaches.Cancer medicine · 2025Review
- High fructose consumption aggravates inflammation by promoting effector T cell generation via inducing metabolic reprogramming.Signal transduction and targeted therapy · 2025Article
- Sweet success in CAR T cells.Nature reviews. Cancer · 2025Article
- Nutritional intervention alleviates T cell exhaustion and empowers anti-tumor immunity.Frontiers in immunology · 2025Review
- Whole grains temper immune-mediated inflammation in Chinese esophageal squamous-cell carcinoma survivors: a multicenter questionnaire study.Frontiers in immunology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Tanya SchildRadiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Patrick WallischMolecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Pharmacology Program, Weill Cornell Graduate School of Medical Sciences, Cornell University, New York, NY 10065, USA.
Yixuan ZhaoRadiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Gerstner Sloan Kettering School for Biomedical Sciences, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Ya-Ting WangImmunology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Lyric HaughtonRadiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Rachel ChirayilRadiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Kaitlyn PierpontMolecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Pharmacology Program, Weill Cornell Graduate School of Medical Sciences, Cornell University, New York, NY 10065, USA.
Kevin ChenAnti-tumor Assessment Core, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Sara Nunes-ViolanteMetabolism Core, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Justin CrossMetabolism Core, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Elisa de StanchinaAnti-tumor Assessment Core, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Craig B ThompsonGerstner Sloan Kettering School for Biomedical Sciences, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
David A ScheinbergMolecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Pharmacology Program, Weill Cornell Graduate School of Medical Sciences, Cornell University, New York, NY 10065, USA; Gerstner Sloan Kettering School for Biomedical Sciences, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Justin S A PerryGerstner Sloan Kettering School for Biomedical Sciences, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Immunology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Kayvan R KeshariRadiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Gerstner Sloan Kettering School for Biomedical Sciences, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. Electronic address: rahimikk@mskcc.org.
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4MT LYMPHOCYTE SUBSET FUNCTION POST-TRANSPLANTATIONP01CA023766 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI PAMER, ERIC G. · 1985 to 2023
$59.0MUnderstanding and Mimicking TCR Recognition with Therapeutic Monoclonal Antibodies.R35CA241894 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI DAVID A SCHEINBERG · 2020 to 2026
$7.2MLeveraging fructose transport to create a privileged substrate to selectively fuel T cellsR01CA248364 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Kayvan R Keshari · 2021 to 2026
$4.3MDevelopment of large-field-of-view hyperpolarized MRIR01CA237466 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI CUNNINGHAM, CHARLES H., HRICAK, HEDVIG · 2020 to 2024
$3.4MVisualizing oxidative stress using hyperpolarized magnetic resonanceR01CA252037 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI KESHARI, KAYVAN R · 2020 to 2024
$3.3MInterrogation of the oxidative-stress-induced leukemia program in vivo usingmetabolic imagingR01CA283578 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Kayvan R Keshari, Michael Kharas · 2023 to 2026
$3.0MRethinking the "quiet" nature of apoptotic cell clearance.DP2GM146337 · NIGMS · SLOAN-KETTERING INST CAN RESEARCH · PI PERRY, JUSTIN S · 2021 to 2024
$2.6MImage-guided Trp-IDO/TDO-Kyn-AHR pathway inhibition, combined with immunotherapyR01CA249294 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI KESHARI, KAYVAN R, MERGHOUB, TAHA · 2021 to 2025
$2.6MMolecular Imaging in Cancer Biology Training ProgramT32CA254875 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Jason S. Lewis, Michael H. Overholtzer · 2021 to 2026
$2.1MNCI NIH HHS P01 CA023766NCI NIH HHS P30 CA008748NCI NIH HHS R01 CA237466NCI NIH HHS R01 CA248364NCI NIH HHS R01 CA249294NCI NIH HHS R01 CA252037NCI NIH HHS R01 CA283578NCI NIH HHS R35 CA241894NCI NIH HHS T32 CA254875NIGMS NIH HHS DP2 GM146337
Abstract
Fructose consumption is elevated in western diets, but its impact on anti-tumor immunity is unclear. Fructose is metabolized in the liver and small intestine, where fructose transporters are highly expressed. Most tumors are unable to drive glycolytic flux using fructose, enriching fructose in the tumor microenvironment (TME). Excess fructose in the TME may be utilized by immune cells to enhance effector functions if engineered to express the fructose-specific transporter GLUT5. Here, we show that GLUT5-expressing CD8
Indexed as
FructoseGlucose Transporter Type 5Metabolic EngineeringNeoplasmsAnimalsCD8-Positive T-LymphocytesCell Line, TumorGlucoseHumansImmunotherapy, AdoptiveMacrophagesMiceMice, Inbred C57BLReceptors, Chimeric AntigenTumor MicroenvironmentXenograft Model Antitumor AssaysFructoseGlucoseGlucose Transporter Type 5Receptors, Chimeric AntigenCAR-Tfructosemacrophagesmetabolic engineeringslc2a5t cell
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.